BCL2 and acute myeloid leukemia: Low-risk patients may also be more sensitive to both sorafenib and midostaurin which are used for AML patients with FLT3 mutations, and to the hedgehog inhibitor vismodegib, but high-risk patients could be more sensitive to the BCL-2 inhibitor ABT-263.